CNS and Neurological Disorders Drug Targets This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Natural Compounds as Inhibitors of A β Peptide and Tau Aggregation
CNS Neurol Disord Drug Targets. 2023 Nov 28. doi: 10.2174/0118715273273539231114095300. Online ahead of print.ABSTRACTNeurodegenerative conditions like Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) encompass disorders characterized by the degeneration of neurons in specific circumstances. The quest for novel agents to influence these diseases, particularly AD, has unearthed various natural compounds displaying multifaceted activities and diverse pharmacological mechanisms. Given the ongoing extensive study of pathways associated with the accumulation of neurofibrillary aggregat...
Source: CNS and Neurological Disorders Drug Targets - November 29, 2023 Category: Drugs & Pharmacology Authors: Kadja Luana Chagas Monteiro Thiago Mendon ça de Aquino Edeildo Ferreira da Silva-J únior Source Type: research

Vasospasm in Pediatric Subarachnoid Hemorrhage
CNS Neurol Disord Drug Targets. 2023 Nov 27. doi: 10.2174/0118715273274147231104160152. Online ahead of print.ABSTRACTCerebral vasospasm (CV) is a common severe complication of subarachnoid hemorrhage (SAH), a severe type of intracranial bleeding that is uncommon in children. The purpose of this article is to review the current literature regarding this potentially devastating complication. CV may be asymptomatic and is less common in children compared to adults. Several molecular phenomena, including inflammatory ones, contribute to its pathophysiology. Better collateral circulation and higher cerebral blood flow are prot...
Source: CNS and Neurological Disorders Drug Targets - November 28, 2023 Category: Drugs & Pharmacology Authors: Ioannis Mavridis Efstratios-Stylianos Pyrgelis Eleni Agapiou Jeries Assi Source Type: research

Intestinal Barrier Function and Neurodegenerative Disease
CNS Neurol Disord Drug Targets. 2023 Nov 24. doi: 10.2174/0118715273264097231116103948. Online ahead of print.ABSTRACTNeurodegenerative diseases are caused by the loss of neurons and/or their myelin sheaths, which deteriorate over time and become dysfunctional. Alzheimer's disease, Parkinson's disease, and multiple sclerosis are among the most prominent neurodegenerative diseases that affect millions of older adults worldwide. Despite extensive research over several decades, controversies still surround the etiology of neurodegenerative diseases, and many of them remain incurable. Meanwhile, an increasing number of new mec...
Source: CNS and Neurological Disorders Drug Targets - November 27, 2023 Category: Drugs & Pharmacology Authors: Shijing Wu Liangfang Yang Yiwei Fu Zhimin Liao De Cai Zhou Liu Source Type: research

Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review
CONCLUSION: TTSs are primarily effective for delivering small molecules. The use of absorption enhancers and irritation mitigators can be necessary to enhance the performance. The development of these technologies is essential for the convenience of patients and caregivers.PMID:37990896 | DOI:10.2174/0118715273275957231102044934 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 22, 2023 Category: Drugs & Pharmacology Authors: Let ícia Basso Silvia Cristina Fagundes Tatiana Staudt Karini da Rosa Elizane Langaro Hamid Omidian Charise Dallazem Bertol Source Type: research

Metabolic Disorder Therapeutics and their Effects on Memory
CNS Neurol Disord Drug Targets. 2023 Oct 25. doi: 10.2174/0118715273269329231013074613. Online ahead of print.ABSTRACTDiabetes is one of the major metabolic disorders of this era. It not only impacts a person's lifestyle but also has a long-term impact on the brain. It has a detrimental effect on a person's health when combined with hypertension and hyperlipidaemia. Several studies have suggested that the incidence of dementia is higher in people with metabolic syndrome. Investigations are underway to determine whether antidiabetic, hypolipidemic, hypercholesteraemic, anti-hypertensive, and other combination medicines can ...
Source: CNS and Neurological Disorders Drug Targets - November 3, 2023 Category: Drugs & Pharmacology Authors: Punita Agarwal Faiz Khan Sugato Banerjee Source Type: research